Samsung Bioepis has successfully opposed Janssen’s bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.
The owner of luxury brand Van Cleef & Arpels has taken retailers Target and Kmart to court, alleging they infringed its trade marks and violated consumer law by selling jewellery that copy its hallmark clover and flower motifs worn by countless celebrities and royalty.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
Explosives company Dyno Nobel is appealing a court’s dismissal of its case seeking to invalidate patents owned by rival Orica for a wireless detonation device.
Dyno Nobel has lost its bid to invalidate three of explosive manufacturer Orica’s patents for a wireless detonation device, with a judge finding it was liable for patent infringement.
Two proponents of Bitcoin Cash have battled before IP Australia over the trade mark ‘Bitcoin Cash City’, with one claiming he coined it in a text message in 2019.
US biotech company Regeneron Pharmaceuticals has sued Sandoz, claiming it is threatening to infringe the patent for its Eylea biologic, used to treat macular degeneration and diabetic macular oedema.